Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01360372 |
Recruitment Status
:
Withdrawn
(No eligible subjects identified)
First Posted
: May 25, 2011
Last Update Posted
: March 17, 2015
|
Sponsor:
Drexel University
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
Michael Sherman, Drexel University
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | March 16, 2011 | ||
First Posted Date ICMJE | May 25, 2011 | ||
Last Update Posted Date | March 17, 2015 | ||
Study Start Date ICMJE | October 2010 | ||
Actual Primary Completion Date | May 2012 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
Hydrogen breath test measure of bowel transit [ Time Frame: 2 days ] On day 1 Hydrogen Breath Test (HBT) measures will occur 30 minutes before test meal, immediately after test meal every 15 minutes until a rise of 5ppm is detected or until 4 hours have passed. On day 2 Hydrogen Breath test measures will occur 30 minutes before test meal, immediately after test meal and every 15 minutes until a rise of 5ppm is detected or until 4 hours have passed.
|
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Change History | Complete list of historical versions of study NCT01360372 on ClinicalTrials.gov Archive Site | ||
Current Secondary Outcome Measures ICMJE |
Gastric residual volume measurement [ Time Frame: 3 days ] Gastric residual volumes will be measured at baseline study entry and then every 4 hours throughout the study until 24 hours post study drug administration.
|
||
Original Secondary Outcome Measures ICMJE | Same as current | ||
Current Other Outcome Measures ICMJE | Not Provided | ||
Original Other Outcome Measures ICMJE | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates | ||
Official Title ICMJE | The Effect Of Methylnaltrexone (Relistor™) on Gut Motility and Tolerance to Tube Feeding in Patients Treated With Opiate Therapy | ||
Brief Summary | It is hypothesized that using methylnaltrexone in addition to pain killer narcotics (opiates) in patients will result in increased tube feeding rates with more frequent nutrition at goal calorie rate. | ||
Detailed Description | Tube feeding rates and tube feeding residual volumes will be measured and followed blinded to the treatment arm (methylnaltrexone vs. placebo) to evaluate if patients (who prior to study entry did not tolerate goal rates tube feeds) can get closer to tube feeding goal with the treatment arm. | ||
Study Type ICMJE | Interventional | ||
Study Phase | Phase 3 | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
||
Condition ICMJE | Tube Feeding | ||
Intervention ICMJE |
|
||
Study Arms |
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Withdrawn | ||
Actual Enrollment ICMJE |
0 | ||
Original Estimated Enrollment ICMJE |
40 | ||
Actual Study Completion Date | May 2012 | ||
Actual Primary Completion Date | May 2012 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years and older (Adult, Senior) | ||
Accepts Healthy Volunteers | No | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | United States | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT01360372 | ||
Other Study ID Numbers ICMJE | Drexel18538 | ||
Has Data Monitoring Committee | Yes | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | Michael Sherman, Drexel University | ||
Study Sponsor ICMJE | Drexel University | ||
Collaborators ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Drexel University | ||
Verification Date | March 2015 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |